Many clinicians believe that the results of revision anterior cruciate ligament (ACL) reconstruction compare unfavorably with primary ACL reconstruction. However, few prospective studies have evaluated revision ACL reconstruction using validated patient-based metrics. This study was performed to evaluate and compare the results of revision ACL reconstruction and primary ACL reconstruction. The Multicenter Orthopaedic Outcomes Network consortium is an NIH-funded, hypothesis-driven, multicenter prospective cohort study of patients undergoing ACL reconstruction. All patients preoperatively complete a series of validated patient-oriented questionnaires. At scheduled 2-year follow-up all patients are given the same series of questionnaires to complete. The study evaluated the results of 2-year follow-up of revision ACL reconstruction performed in 2001. Parameters evaluated included Marx activity level, Knee Injury and Osteoarthritis Outcome Score (KOOS), and International Knee Documentation Committee (IKDC) scores. For this study 446 subjects met inclusion criteria; 2-year follow-up was obtained on 393 (88%). The study group consisted of 55% males with median age of 22 years. There were 33 revision ACL reconstruction cases, for which follow-up was available for 29 (88%). Median baseline Marx (interquartile range) was 12 (8 to 16) and 12 (6 to 16) for the primary ACL reconstruction and revision ACL reconstruction groups, respectively (p ¼ 0
with primary ACL reconstruction. IKDC and KRQOL were significantly decreased in revision ACL reconstruction compared with primary ACL reconstruction at 2-year followup. Revision ACL reconstruction resulted in a significantly worse outcome as measured by these patient-based measures at 2 years.
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Anterior cruciate ligament (ACL) reconstruction continues to be a commonly performed procedure. [1] [2] [3] More than 200,000 ACL injuries are estimated to occur annually in the United States and more than 175,000 ACL reconstructions are performed each year. 4, 5 The initial cost of ACL reconstructions in the United States exceeds $2 billion, and there is evidence that the number of these procedures is increasing. 5, 6 The past 20 years has resulted in significant advances in the surgical reconstruction of the ACL. With these advances has come increased expectations of outcome and currently many surgeons will describe a surgical reconstruction with a greater than 90% success rate. 7 With these improved results has come the belief by patients that should problems develop a revision reconstruction can be performed with similar results to primary reconstructions. While high levels of evidence may be lacking it does not appear that any series of ACL revision reconstruction has met or exceeded the results of a series of primary reconstructions. [8] [9] [10] The Multicenter Orthopaedic Outcomes Network (MOON) has established a prospective longitudinal cohort to evaluate the results of ACL reconstruction including primary and revision patients. This allows us to compare and contrast the results of revision versus primary reconstruction in a series of patients collected during the same time frame by the same set of surgeons utilizing the same validated patient-based outcome measures. Our hypothesis is that revision ACL reconstruction results in worse outcome as measured by patient-based outcome measures specifically the Marx activity level, Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales, and International Knee Documentation Committee (IKDC) Subjective form.
METHODS
The MOON consortium is an NIH-funded, hypothesisdriven, multicenter prospective cohort study of patients undergoing ACL reconstruction. Members of the MOON consortium began enrolling ACL reconstruction patients in a prospective protocol following Investigational Review Board approval obtained from each of six sites (Washington University in St Louis, Vanderbilt University Sports Medicine, Cleveland Clinic Foundation, Ohio State University, University of Iowa, and Hospital for Special Surgery) by eight physicians (RWW, KPS, CK, ECM, AA, RDP, JTA, RGM).
A prospective longitudinal cohort design was established to determine the demographics, associated injuries, and outcomes of revision ACL reconstruction. Patients preoperatively completed a questionnaire documenting demographics, injury mechanism, patient-based outcome measures, history of previous knee surgery, and activity level. The attending surgeon completed a form documenting examination under anesthesia (EUA) and status and treatment of meniscal and articular cartilage injuries. Previous studies have demonstrated the group's interrelater agreement on meniscal and chondral pathology. 11, 12 The details of ACL reconstruction and rehabilitation milestones are recorded as previously described. 13, 14 A variety of reconstructive grafts were used among the participating surgeons. These included ipsilateral and contralateral autografts, and Achilles, patellar tendon, and soft tissue allografts. More detailed description of the surgeon documentation is detailed in previous studies. 13, 14 At 2-year follow-up patients were contacted and once again filled out the questionnaire and reported any additional injuries and surgeries. Patient-based outcome measures obtained by the questionnaire include the KOOS, IKDC Subjective form, and the Marx activity level score.
RESULTS
Between January 1, 2002 and December 31, 2002, 446 patients met inclusion criteria for this study having had a unilateral primary or revision ACL reconstruction. At 2 years, follow-up was obtained on 393 (88%). After excluding those who had additional collateral ligament surgery (n ¼ 29), there were 364 subjects included in the analyses. Additional treatment of chondral and meniscal lesions was not excluded. The study group consisted of 55% males with median age of 22 years. There were 38 revision ACL reconstructions enrolled in the MOON prospective longitudinal cohort. At the time of enrollment, median age for these 38 patients was 26 (range, 16 to 49 years). There were 27 males and 11 females. Of the 38 revision cases, 5 were excluded due to concomitant collateral ligament surgery, leaving 33 revision ACL reconstruction patients meeting the inclusion criteria, and of these 29 (88%) were available for 2-year followup. The total of 20 males and 9 females participated in 2-year follow-up.
Median baseline Marx (interquartile range) was 12 (8 to 16) and 12 (6 to 16) for the primary ACL reconstruction and revision ACL reconstruction groups, respectively (p ¼ 0.81) ( Table 1) . At 2 years, median Marx was 9 (4 to 13) and 5 (0 to 10) for the primary ACL reconstruction and revision ACL reconstruction groups, respectively (p ¼ 0.03). Median 2-year IKDC was 75.9 (revision) versus 83.9 (primary) (p ¼ 0.003). Median KOOS subscale Knee Related Quality of Life (KRQOL) at 2 years was 62.5 (revision) versus 75 (primary) (p < 0.001) (Fig. 1) 
DISCUSSION
Our results demonstrate that revision ACL reconstruction results in a worse outcome than primary ACL reconstruction as measured by validated patient-based outcome measures. The differences demonstrated were both statistically and clinically significant. This occurred in a prospective longitudinal cohort performed by the same surgeons during the same time period utilizing the same measurement tools (Marx activity level, KOOS, and IKDC).
The Marx activity scale is a validated, quickly administered activity measure to use in addition to joint specific outcome measures and general health outcome measures. 15 The Marx activity level was developed to assess functional activity rather than sport activity, and to quantify the frequency of the activity. It consists of only four questions. The patient's peak activity level over the past year is measured by these four questions assessing running, cutting, decelerating, and pivoting. Items are scored from 0 to 4 depending on frequency performed from less than one time per month (0 points) to 4 or more times per week (4 points). Thus, scores range from 0 to 16. It has undergone validation testing in its development. 15 At 2-year follow-up median Marx activity level scores were 9 for primary reconstructions versus 5 for revision reconstructions. Unfortunately, additional studies have not been performed utilizing the Marx activity level to determine a minimal clinically important difference in scores and thus we cannot unequivocally state that a difference of 3 points on the Marx activity level score represents a clinically significant difference. We speculate that a change in score of 2 points (more than a 10% of total possible score) is likely a clinically significant difference. The present study found a statistically significant difference between primary (Marx 9) and revision reconstructions (Marx 5) p ¼ 0.03 at 2-year follow-up. In our study a difference of 4 points (p ¼ 0.009) represents a 33% change of a total score of 16, and while it probably represents a clinically significant difference further research is necessary. Our study utilized the IKDC Subjective form. The IKDC was established in 1987 and developed a standardized outcome measure evaluating knee injuries and treatment first published in 1993. The board of the American Orthopaedic Society for Sports Medicine (AOSSM) moved in 1997 to revise the form. 16 The new subjective form consists of 18 questions. The raw scores are transformed to a 0 to 100 scale. 16 This new form has been validated for a variety of knee conditions including ligament and meniscus injuries. 17, 18 The minimal clinically important difference in scores has been determined and a change in score of 11.5 points on the 100 point scale represents a significant change. 18 It can be used for a variety of ages and gender. 19 Our revision median score was 75.9 versus primary median score of 83.9. This represented a statistically different result but not clinically significant difference of IKDC scores.
The KOOS was developed by Eva Roos as the first sport-specific patient-based outcome measure. Its goal was to assess outcome in the young and middleaged athletes. It included the Western Ontario and McMaster Universities (WOMAC) scores to assess osteoarthritis. 20, 21 The KOOS evaluates five dimensions measured separately: Pain (nine items), Symptoms (seven items), ADLs (17 items), Sport and Recreation function (five items), and KRQOL (four items). 20 To assess osteoarthritis in the older individuals the 24 questions of the WOMAC were included. 20 Each subscale is summed and transformed to a 0 (worst possible) to 100 (best possible) score. Previous studies have determined that a change in score or difference in score of 8 points or greater represents a minimal clinically important difference. 21 The KOOS has been used for the assessment of a variety of knee conditions including ACL reconstructions. [22] [23] [24] [25] [26] The Pain, Sport and Recreation, and KRQOL subscales have been determined to be the most sensitive to a change in the condition of the knee. In our study KRQOL demonstrated a difference of 12.5 points between revision and primary ACL reconstructions. Thus, this was a statistically and clinically significant worse outcome for revisions on the most sensitive KOOS subscale. The Sports and Recreation subscale difference was 10 points and represented a clinically significant difference and was statistically different between the two groups. The Pain subscale difference was 8.4 points and probably represented a clinically significant difference and was statistically different between the two groups. All other subscales had differences less than 10 points and while statistically significant may not represent clinically significant differences. The ADLs as expected was virtually identical between primary and revision reconstructions (97. Few revision ACL reconstruction studies have utilized validated patient-based outcome measures. In fact, no revision ACL reconstructions study has used Marx activity scores. The IKDC has been infrequently utilized. Our median IKDC score at 2-year follow-up was 79.4. Recently Battaglia et al reported 95 revision ACL reconstructions at a mean follow-up period of 72.7 months. 9 The IKDC subjective scores for the patients they deemed excellent averaged 79.7; 63.1 in the fair group and 56.2 in the poor group. All of their groups on average scored lower than age-matched norms. Fox et al in a retrospective case series of ACL revision reconstructions utilizing nonirradiated fresh frozen patellar tendon allograft evaluated outcome using a variety of patient-based outcome measures. 27 At a minimum of 2-year follow-up (average age, 4.8 years) their IKDC mean score was 71. They reported KOOS subscales of Pain, Symptoms, and ADLs. KRQOL and Sports and Recreation subscales were not reported. Their mean pain score was 84, similar to our median score of 83.3. The Symptoms subscale mean score was 77 compared with our 78.6. The ADLs subscale mean for the Fox study was 91 versus 97.1 median score in our study.
Our study have several strengths and a few limitations. This represents one of the few studies utilizing prospective data. In addition, the ability to directly compare the results to a similar primary ACL reconstruction cohort collected at the same time by the same surgeons has previously not been available. Our followup is short at 2 years and additional length of follow-up will be valuable. Despite a large cohort, less than 10% are revision ACL reconstructions. Thus, our study number is small. This precludes the ability to do multivariable analysis to determine predictors of outcome. Future studies such as those being performed by the Multicenter ACL Revision Study (MARS) group will be necessary to accumulate a cohort large enough to allow this more sophisticated analysis.
In conclusion the Marx activity score declined at 2-year follow-up in revision ACL reconstruction compared with primary ACL reconstruction. IKDC and KOOS subscales KRQOL, Sports and Recreation, and Pain were significantly decreased in revision ACL reconstruction compared with primary ACL reconstruction at 2-year follow-up. Revision ACL reconstruction resulted in a significantly worse outcome as measured by these patient-based measures at 2 years.
